New hope for kids with rare muscle disease: long-term drug safety trial underway
NCT ID NCT06540144
First seen Sep 30, 2025 · Last updated May 07, 2026 · Updated 24 times
Summary
This study looks at the long-term safety of a drug called rozanolixizumab in children aged 2 and older with generalized myasthenia gravis, a condition that causes muscle weakness. Participants who completed a previous study can join. The main goal is to track serious side effects over multiple 6-week treatment cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mg0008 20081
Taipei, Taiwan
-
Mg0008 20095
Taipei, Taiwan
-
Mg0008 20339
Ōbu, Japan
-
Mg0008 20340
Fuchu-shi, Japan
-
Mg0008 20343
Sagamihara, Japan
-
Mg0008 40144
Milan, Italy
-
Mg0008 40155
Warsaw, Poland
-
Mg0008 40290
Bologna, Italy
-
Mg0008 40733
Naples, Italy
-
Mg0008 40734
Warsaw, Poland
Conditions
Explore the condition pages connected to this study.